Immunovant, Inc. (NASDAQ: IMVT) is a clinical-stage biopharmaceutical company dedicated to developing targeted therapies for patients with autoimmune and inflammatory diseases. The company focuses on the neonatal Fc receptor (FcRn) pathway, aiming to reduce pathogenic immunoglobulin G (IgG) autoantibodies through monoclonal antibodies designed for subcutaneous administration. Its lead candidate, IMVT-1401, is currently being evaluated in Phase 2 and Phase 3 trials for indications such as myasthenia gravis, thyroid eye disease (Graves’ orbitopathy), warm autoimmune hemolytic anemia and immune thrombocytopenia.
Immunovant’s pipeline centers on next-generation FcRn antagonists intended to offer improved dosing convenience and safety profiles compared with existing therapies. Preclinical programs are advancing additional FcRn modulators with the potential to treat a broad range of autoimmune conditions. The company’s R&D efforts are supported by robust translational science, biomarker strategies and patient-focused trial designs to accelerate program milestones and regulatory interactions.
Founded in 2016 as a subsidiary of Roivant Sciences, Immunovant raised capital through a Nasdaq initial public offering in late 2020. Headquartered in New York City with research facilities in Switzerland, the company operates global clinical trial sites across North America, Europe and Asia. Strategic collaborations and regulatory engagements are in place to support eventual product registrations and commercial launches in core markets.
Immunovant’s executive leadership team combines decades of experience in immunology and drug development, with senior professionals who have held roles at leading biopharmaceutical companies including Amgen, Genentech and Pfizer. The board of directors comprises industry experts guiding the company’s strategic direction as it advances toward delivering novel, patient-centric treatments for debilitating autoimmune disorders.
AI Generated. May Contain Errors.
